Literature DB >> 8331574

Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.

K Chiba1, K Kobayashi, K Manabe, M Tani, T Kamataki, T Ishizaki.   

Abstract

Oxidative metabolism of omeprazole (OPZ) was studied in 14 human liver microsomes in relation to the 4'-hydroxylation capacity of S-mephenytoin. The formation of 5-hydroxyomeprazole and omeprazole sulfone (OPZ-SFN) from OPZ exhibited a biphasic kinetic behavior, indicating that at least two distinct enzymes are involved in either of the metabolic pathways of OPZ. By using a two-enzyme kinetic approach, the activities were described by high (Km1 and Vmax1)- and low-affinity components (Km2 and Vmax2). The respective mean (+/- S.D.) kinetic parameters for 5-hydroxylation and sulfoxidation were: Km1 = 6.0 +/- 2.4 and 10.2 +/- 7.2 microM and Vmax1 = 88.0 +/- 70.2 and 66.9 +/- 53.9 pmol/mg/min; Km2 = 106 +/- 127 and 482 +/- 472 microM and Vmax2 = 116 +/- 88 and 299 +/- 131 pmol/mg/min. Among these kinetic parameters, only the Vmax1 of 5-hydroxylation gave a close correlation with the corresponding parameter of S-mephenytoin (rs = 0.911, P < .01). In addition, OPZ and S-mephenytoin inhibited competitively each other's metabolism with the respective Ki values of 2.0 and 162 microM. Interestingly, OPZ-SFN also inhibited competitively 4'-hydroxylation of S-mephenytoin with a Ki value of 8.2 microM. Moreover, polyclonal antibodies raised against S-mephenytoin 4'-hydroxylase (P450 form) partially inhibited the 5-hydroxylation of OPZ, whereas no inhibition was observed for the sulfoxidation. These findings suggest that S-mephenytoin 4'-hydroxylase is an enzyme primarily responsible for the 5-hydroxylation of OPZ and further metabolism of OPZ-SFN, but not for the sulfoxidation of OPZ in human liver microsomes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8331574

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

1.  Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes.

Authors:  Z H Xu; W Wang; X J Zhao; S L Huang; B Zhu; N He; Y Shu; Z Q Liu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes.

Authors:  C Senda; Y Yamaura; K Kobayashi; H Fujii; H Minami; Y Sasaki; T Igarashi; K Chiba
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

3.  One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.

Authors:  Takuma Kagami; Mitsushige Sugimoto; Hitomi Ichikawa; Shu Sahara; Takahiro Uotani; Mihoko Yamade; Yasushi Hamaya; Moriya Iwaizumi; Satoshi Osawa; Ken Sugimoto; Hiroaki Miyajima; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2015-10-02       Impact factor: 2.953

4.  Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study.

Authors:  Laurian Vlase; Maria Neag; Adina Popa; Dana Muntean; Sorin E Leucuta
Journal:  Curr Ther Res Clin Exp       Date:  2010-12

5.  Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.

Authors:  Yong-Mei Hu; Qiao Mei; Xin-Hua Xu; Xiang-Peng Hu; Nai-Zhong Hu; Jian-Ming Xu
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

6.  Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.

Authors:  Tsukasa Uno; Takenori Niioka; Makoto Hayakari; Norio Yasui-Furukori; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Eur J Clin Pharmacol       Date:  2007-01-04       Impact factor: 2.953

7.  Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes.

Authors:  Li-Jun Yang; Lan Fan; Zhao-Qian Liu; Yan-Mei Mao; Dong Guo; Li-Hui Liu; Zhi-Rong Tan; Liang Peng; Chun-Ting Han; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2009-01-27       Impact factor: 2.953

8.  Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.

Authors:  K Yoshimoto; H Echizen; K Chiba; M Tani; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

Review 9.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.

Authors:  K Chiba; A Saitoh; E Koyama; M Tani; M Hayashi; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.